Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers

This study is intended to provide information from subjects who currently have painful, chronically open wounds and assess the pain reduction capacity of KeraStat® Gel with Morphine. In gathering data from subjects who have baseline pain from their chronically open wounds, the investigators can then evaluate the capacity of KeraStat® Gel plus Morphine in reducing the subjects daily pain levels, pain associated with dressing changes, and pain medication consumption.

Study Overview

• Status: Recruiting
• Conditions: Burns; Wound of Skin
• Intervention / Treatment: Drug: KeraStat® Gel with Morphine application; Drug: KeraStat® Gel application

Detailed Description

Chronic wounds pose a serious challenge to wound care professionals, as open and non-healing ulcers are often painful and difficult to treat. Patients are less compliant because of their pain and also run the risk of increased pain medication exposure in treating these wounds. A great deal of healthcare resources are dedicated to the treatment of non-healing open wounds. KeraStat® Gel offers a novel method for the topical delivery of Morphine to manage pain during the treatment of healing these problematic wounds.

Proof of concept work showed that a single treatment application of opioid-loaded keratin hydrogels produced extended analgesia that lasted up to two days in both sensitized and non-sensitized models of pain in rodents. This work then moved the proposed product into a porcine large animal study that showed topical morphine did not delay wound healing or re-epithelization and did not impact dermal thickness or Transforming Growth Factor Beta 1 (TGF1). Additionally, pharmacokinetics assessments showed that topical delivery of morphine to a burn wound resulted in no detectable morphine in animal serum.

KeraStat® Gel is a sterile, non-implantable, water-based gelatinous (hydrogel) wound dressing intended to act as a protective covering in the management of a variety of partial thickness dermal wounds. Keratin is a structural, filamentous protein that, when hydrated, forms a hydrogel that provides coverage and maintains a moist environment for injured skin, similar to collagen and other extracellular matrix molecules used in existing products. Therefore, KeraStat® Gel is expected to behave in an equivalent manner to conventional biopolymer wound dressings. ISO 10993 biocompatibility studies and performance testing, both in vitro and in vivo, indicated that KeraStat® Gel is safe and biocompatible. Additionally, two clinical studies support the assertion that the product is non-sensitizing, non-irritating, and does not produce a humoral response. The current study is designed to provide pilot data to inform a power calculation to determine whether KeraStat® Gel plus Morphine reduces pain associated with dressing changes which may secondarily reduce daily pain and pain medication consumption.

This study is intended to evaluate the efficacy of KeraStat® Gel with Morphine in treating and/or minimizing the pain associated with chronic open wounds and subsequently replace or reduce the need for systemic analgesia.

Long-term impacts include improving tolerance to dressing changes resulting in better adherence to the treatment of painful open wounds, as well as giving providers an alternative to systemic narcotics which are dangerous, have many negative side effects, and are highly addictive. Data from this project will also support further studies in evaluating and assessing patients who have painful wounds and their chronic management.

• Study Type: Interventional
• Enrollment (Anticipated): 24
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Victoria Diaz, RN; Phone Number: 210-916-5760; Email: Diaz@metisfoundationusa.org

Study Locations

• United States
  • Texas
    • San Antonio, Texas, United States, 78229
      • Recruiting
      • South Texas Aesthetic and Reconstructive Surgery
      • Contact: Victoria Diaz; Phone Number: 210-569-1140; Email: diaz@metisfoundationusa.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subjects age 18 or older able to provide informed consent.
2. Ulcer size 1-300 cm2

4. Undermining/tunneling <3 cm from wound margin 5. Grossly free of necrotic and/or infected tissue 6. Baseline minimum of 2 on VAS pain scale

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from the study:

1. Known allergy to the standard of care or any of the ingredients in KeraStat® Gel or to morphine
2. Wound has heavy or high-volume exudate or necrotic tissue
3. Clinical signs of infection or contamination of the wound
4. Subjects unable to complete the VAS pain score in pain journal
5. Pregnant or nursing
6. Prisoner
7. Any condition the Investigator determines will compromise subject safety or prevent the subject from completing the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: KeraStat® Gel with Morphine; Administration and application of KeraStat® Gel with Morphine (Bi-Weekly): KeraStat® Gel with Morphine will be formulated by mixing liquid Morphine 25mg/mL into 5mg of KeraStat, this will be individually packaged in 5mL tubes at a concentration of 5mg/mL. Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject. Home Administration and application of KeraStat® Gel with Morphine (Every 1-3days): Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel with Morphine in 5mL tubes. Instructions for application as above will be taught to subjects and instructions will be provided as subjects themselves or designated caretakers or home-care personnel will change their dressings as instructed by their physician with the addition of KeraStat® Gel administration as outlined above.	Drug: KeraStat® Gel with Morphine application; Administration and application of KeraStat® Gel with Morphine (Bi-Weekly): KeraStat® Gel with Morphine will be formulated by mixing liquid Morphine 25mg/mL into 5mg of KeraStat, this will be individually packaged in 5mL tubes at a concentration of 5mg/mL. Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject. Home Administration and application of KeraStat® Gel with Morphine (Every 1-3days): Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel with Morphine in 5mL tubes.
Active Comparator: KeraStat® Gel; Administration and application of KeraStat® Gel (Bi-Weekly): Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject. Home Administration and application of KeraStat® Gel (Every 1-3days): Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel 5mL tubes. Instructions for application as above will be taught to subjects and instructions will be provided as subjects themselves or designated caretakers or home-care personnel will change their dressings as instructed by their physician with the addition of KeraStat® Gel administration as outlined above.	Drug: KeraStat® Gel application; Administration and application of KeraStat® Gel (Bi-Weekly): Each 5mL tube will cover and area of 300cm2 which is approximately 1.5% TBSA of an average, 60kg subject. Home Administration and application of KeraStat® Gel (Every 1-3days): Dressing is to be changed every 1-3 days, no more than once a day. Subjects will be provided the appropriate amount of pre-compounded KeraStat® Gel in 5mL tubes.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Visual Analog Scale	This unidimensional measure is composed of a line, usually 10 centimeters in length, anchored by two verbal descriptors representing the symptom extremes ("no pain" and "worst imaginable pain") and 6 facial expression anchors.	Day 0 and Every 2 weeks for up to 12 weeks
Change in Adverse event assessment	Assessment of adverse events throughout the course of the subject treatment.	Day 0 and Every 2 weeks for up to 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Pressure Sore Quality of Life questionnaire	Standardized method to assess wound specific symptoms and functional outcomes for quantifying the benefits of associated interventions. The questionnaire is composed of 11 questions with 4 answer boxes for each question, the subject is asked to check one of the four boxes to evaluate the wound. The boxes are labeled No bother at all, A little bother, A lot of bother, and I had this problem but not because of my pressure sores.	Day 0 and Every 2 weeks for up to 12 weeks

Collaborators and Investigators

• Sponsor: The Metis Foundation

Study record dates

Study Major Dates

• Study Start (Actual): May 11, 2021
• Primary Completion (Anticipated): May 31, 2022
• Study Completion (Anticipated): May 31, 2022

Study Registration Dates

• First Submitted: January 5, 2022
• First Submitted That Met QC Criteria: January 19, 2022
• First Posted (Actual): February 1, 2022

Study Record Updates

• Last Update Posted (Actual): February 1, 2022
• Last Update Submitted That Met QC Criteria: January 19, 2022
• Last Verified: January 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Wounds and Injuries; Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Opioid; Narcotics; Morphine
• Other Study ID Numbers: KeraStat

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes